Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. currently has 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 6 distinct examiners, meaning each pending matter is assigned to a different individual. The prosecution is spread across 3 distinct art units, which suggests some technical variety within the company's biological and pharmaceutical filings.
The busiest examiner for this portfolio is WHITE, DAWANNA SHAR-DAY, who handles 1 pending office action. With a total of 6 pending office actions, the workload is perfectly distributed, and no single examiner has a dominant role in the current prosecution. This requires the applicant to manage separate examiner relationships while navigating the procedural nuances of 3 distinct art units. The focus on Biotechnology & Pharmaceuticals ensures that the technical scope remains within a defined field.
Managing 6 pending office actions across multiple examiners requires a coordinated effort to maintain consistency. Since WHITE, DAWANNA SHAR-DAY and the other examiners are working within only 3 distinct art units, there may be some overlap in the technical standards applied to the cases. Practitioners should look for commonalities in the feedback from the art units to streamline their responses. This structure allows for a relatively focused approach to the company's intellectual property goals in the pharmaceutical sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| SEAMAN, D MARGARET M | 1 | 76.5% | +8.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 71d |
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18723812 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JACKSON, SHAWQUIA | — |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | — |
| 18293637 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | REDWOOD, CHRISTOPHER EVAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 71d |
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833879 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18723812 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JACKSON, SHAWQUIA | — | §102§112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18685883 | AROMATIC RING-CONTAINING BIOLOGICAL ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BAUER, NICOLA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18293637 | CYCLOALKENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18551180 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18017666 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 71d | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial